Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05772416
Other study ID # 4313
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2021
Est. completion date August 31, 2025

Study information

Verified date March 2023
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Eugenio Mercuri, MD
Phone +39 063015
Email eugeniomaria.mercuri@policlinicogemelli.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims to establish the diagnostic vcalue of a structured neurological examination to detect eraly neurological abnormlaities in infants at risk of neurological abnormlaiyies.


Description:

The study aims to establish the diagnostic vcalue of a structured neurological examination to detect eraly neurological abnormlaities in infants at risk of neurological abnormlaiyies. Infants at risk of neurological abnormlaiyies, such as very pèretrm infants and infants with asphyxia or with overt neyurologocal abnormla signs suh as convilsions will be assessed with a structured neurological examination and followed over time.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date August 31, 2025
Est. primary completion date August 31, 2025
Accepts healthy volunteers
Gender All
Age group 6 Hours to 1 Week
Eligibility Inclusion Criteria: all newborns with neonatal encephaolopathy or at risk for neurological abnormlaities, such as preterm infants born below 34 weeks or those with convusions Exclusion Criteria: families unwilling to sign consent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Italy Policlinico gemelli Rome

Sponsors (1)

Lead Sponsor Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hammersmith Neonatal and infant Neurological examination neurological examination witha score from 0 to 75 with 75 indicating best performance 5 years
See also
  Status Clinical Trial Phase
Completed NCT05471336 - Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE) N/A
Recruiting NCT05514340 - Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy Phase 2
Recruiting NCT04603547 - Transcutaneous Carbon Dioxide Monitoring in Neonates Receiving Therapeutic Hypothermia for Neonatal Encephalopathy
Completed NCT01913340 - Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) Phase 1/Phase 2
Completed NCT00581581 - CoolCap Followup Study-Coordination of Participating Centers N/A
Completed NCT03122808 - Uterine Activity in Moderate-Severe Neonatal Encephalopathy: A Case Control Study
Recruiting NCT02544100 - Neonatal Neurologic Intensive Care Network of China
Completed NCT03380013 - OMT to Improve Feeding After Hypothermia N/A
Active, not recruiting NCT03409770 - Optimising the Duration of Cooling in Mild Encephalopathy N/A
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Not yet recruiting NCT06098833 - Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia Phase 2
Not yet recruiting NCT05756296 - The Long-term Consequences of Neonatal Encephalopathy in the Hypothermia Era
Recruiting NCT04432662 - Darbepoetin in Neonatal Encephalopathy Trial Phase 2
Recruiting NCT02793999 - Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
Not yet recruiting NCT05889507 - Cooling in Mild Encephalopathy N/A
Recruiting NCT05848271 - Natural History Study of Patients With HPDL Mutations
Not yet recruiting NCT04176471 - TIME Study: Therapeutic Hypothermia for Infants With Mild Encephalopathy N/A
Completed NCT01309711 - Magnetic Resonance Biomarkers in Neonatal Encephalopathy
Recruiting NCT04225975 - Neonate Cerebral Activity in Immediate Post Partum N/A
Recruiting NCT05610085 - A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures Phase 2